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Levels of zinc, along with its mechanistically related metabolites citrate and aspartate, are widely 
reported as reduced in prostate cancer compared to healthy tissue, and are therefore pointed out as 
potential cancer biomarkers. Previously, it has only been possible to analyze zinc and metabolites by 
separate detection methods. Through matrix-assisted laser desorption/ionization mass spectrometry 
imaging (MSI), we were for the first time able to demonstrate, in two different sample sets (n=45 and 
n=4), the simultaneous spatial detection of zinc, in the form of ZnCl3-, together with citrate, aspartate 
and N-acetylaspartate on human prostate cancer tissues. The reliability of the ZnCl3- detection was 
validated by total zinc determination using laser ablation inductively coupled plasma MSI on adjacent 
serial tissue sections. Zinc, citrate and aspartate were correlated with each other (range r=0.46 to 0.74) 
and showed a significant reduction in cancer compared to non-cancer epithelium (p<0.05, log2fold 
change range: -0.423 to -0.987), while no significant difference between cancer and stroma tissue was 
found. Simultaneous spatial detection of zinc and its metabolites is not only a valuable tool for 
analyzing the role of zinc in prostate metabolism, but might also provide a fast and simple method to 
detect zinc, citrate and aspartate levels as a biomarker signature for prostate cancer diagnostics and 





Healthy prostatic epithelial cells have a unique metabolism, with an extraordinary high production 
and secretion of the metabolite citrate and a very high zinc concentration.1 Citrate production is 
facilitated through zinc mediated inhibition of aconitase. This enzyme is responsible for converting 
citrate to isocitrate in the tricarboxylic acid (TCA) cycle, and inhibition causes citrate accumulation1 
(Figure 1). It is proposed that imported aspartate serves as one of the main carbon sources for citrate, 
by conversion through oxaloacetate.2 Aspartate can also be created from or converted to N-
acetylaspartate (NAA),3 but this potential mechanism is less investigated in prostate cells. Altered 
metabolism is one of the key characteristics of prostate cancer (PCa)4 and during the course of cancer 
development, both citrate and zinc levels are reduced compared to healthy prostatic tissue, and are 
therefore proposed as prostate cancer biomarkers.1, 5-7 
 
 
Figure 1: Metabolic alterations in prostate cancer as a consequence of reduced zinc levels. (a) In 
healthy prostate epithelial cells a high intake of zinc inhibits the conversion of citrate to isocitrate, 
causing accumulation of citrate. Increased aspartate intake functions as a carbon source for citrate 
production. (b) In malignant prostate epithelial cells, reduced levels of zinc leads to citrate being 
utilized further into the TCA-cycle. Abbreviation: NAA = N-acetylaspartate. 
 
Detection of zinc in human prostate tissue has previously been performed by methods such as atomic 
absorption spectrometry,8 X-ray fluorescent spectrometry,6 inductively coupled plasma mass 
spectrometry (ICP-MS)9 and zinc-specific fluorescent staining of tissue sections.7, 10 Laser ablation 
(LA) ICP MS imaging (MSI) has additionally been used to image zinc distribution in mouse brain 
tissue11, breast cancer12 and prostate cancer tissue.13 Even though these are robust methods for zinc-
detection, they do not allow for the simultaneous detection of other biomolecules such as metabolites 
and lipids. Hence, studies of the zinc-citrate-aspartate pathway have until now required the use of 
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different methods on different pieces of tissue. Matrix assisted laser/desorption ionization (MALDI) 
MSI is a method suitable for spatial detection of a number of different metabolites and lipids, and is 
becoming popular for analysis of heterogeneous cancer tissue.14 Hou et al. demonstrated detection of 
zinc, among other metal ions, using MALDI, but did not detect zinc in human urine or blood samples, 
nor mouse brain tissue sections.15 However, as the zinc content in prostate is uniquely high compared 
to other tissues and biofluids,1 MALDI MSI may be a suitable method to detect zinc in prostate tissue. 
In this study, we demonstrate the use of MALDI time-of-flight (TOF) MSI for simultaneous spatial 
detection of zinc (in the form of ZnCl3-) and the relevant metabolites citrate, aspartate and NAA in 
prostate cancer tissue sections. Comparing MALDI-TOF measured ZnCl3- to total zinc concentration 
detected with LA-ICP-MS confirmed that ZnCl3- is representative of the total zinc concentration in the 
tissue. This is the first time zinc has been detected together with other relevant metabolites in this 
important prostate cancer pathway through the exact same measurement. 
 
2. Material and Methods 
Sample collection and preparation 
This study was approved by the Regional Committee for Medical Health and Research Ethics of Mid-
Norway (identifier 2017/576) and all procedures followed national and EU ethical regulations. All 
patient donors signed an informed written consent before the tissue samples were collected. 
Samples included in this study were fresh frozen prostate samples collected after radical 
prostatectomy of confirmed malignant prostates, and stored at either -80° Celsius or in liquid nitrogen. 
Two different types of samples were used; the ‘core samples’ (n=45 samples, N=15 patients) were 
disc-shaped samples (height 2mm, Ø 3mm) collected as described by Bertilsson et al.16 from 2 mm 
thick frozen tissue slices. The ‘biopsy samples’ (n=4 samples, N=4 patients) were collected with 
biopsy needles and were further embedded in 5% carboxymethyl cellulose (CMC) and 10% gelatin as 
described by Nelson et al.17 All samples to be analyzed by MALDI MSI were cryosectioned at 4 µm 
and mounted onto indium tin oxide (ITO) covered glass slides (Bruker Daltonics, part nr. 9237001, 
Bremen, Germany). Three of the core samples and one of the biopsy samples were re-sectioned at a 
later point to produce several adjacent tissue sections, the validation sample sets, for additional 
experiments including LA-ICP MSI, re-measurement with MALDI-TOF MSI and MALDI-Orbitrap. 
Tissue sections to be measured with LA-ICP-MS were cut at 10 µm and mounted onto regular light 
microscope glass slides. An overview of the methodological workflow is presented in Figure 2. All 




Figure 2: Workflow overview. Two fresh frozen prostate cancer sample sets, the core samples and 
the biopsy samples, were cryosectioned, mounted onto indium tin oxide (ITO) covered glass slides 
and covered with N-(1-naphthyl) ethylenediamine dihydrochloride (NEDC) and 9-aminoacridine (9-
AA) hydrochloride monohydrate matrix, respectively. Both sample sets were measured with MALDI-
TOF MSI. Three of the core samples and one biopsy sample were sectioned for validation analysis, 
including re-measurement with MALDI-TOF MSI using NEDC matrix, MALDI-TOF MSI with 
chloride-free 9-AA matrix, high mass resolution MALDI-Orbitrap and total zinc detection with LA-
ICP-MSI. Standards of ZnCl2 were also measured with MALDI-TOF. 
 
All tissue sections were vacuum dried (>30 min) prior to data acquisition and sections prepared for 
MALDI MSI experiments were covered with matrix. As both sample sets used in this study originally 
were separate pilot experiments, two different matrix application methods were used. For the core 
samples, the TM-Sprayer M3 (HTX Technologies LLC, Carrboro, USA) was used to apply 14 layers 
of 7 mg/mL N-(1-Naphthyl) ethylenediamine dihydrochlorid (NEDC) (Sigma-Aldrich, Gillingham, 
UK) dissolved in 70% methanol. The biopsy samples were covered with 8 layers of 10 mg/mL 9-
aminoacridine hydrochloride monohydrate (9-AA HCl H2O) (Sigma-Aldrich) mixed in 70% 
methanol, applied with SunCollect (SunChrom, Friedrichsdorf, Germany). It was suspected that the 
available chloride ions present in both matrices used could contribute to the formation of ZnCl3-. To 
investigate this potential effect, one of the validation sample sets were covered with 9-AA without 
hydrochloride monohydrate (9-AA) (Sigma-Aldrich), using the same concentration and spraying 
parameters as for 9-AA HCl H2O. Exact spraying parameters for all matrices are presented in 
Supplementary Table S1. 
MALDI MSI data acquisition 
MALDI-TOF MSI was performed on all samples using a rapifleXTM MALDI-TOF TissuetyperTM 
(Bruker Daltonics) operating reflector negative ion mode across a mass range of m/z 40-1000, 
acquiring 200 shots per pixel at a 10 kHz frequency. The core samples and the biopsy samples were 
6 
 
measured with pixel sizes of 30 µm and 50 µm, respectively. The rapifleX instrument was calibrated 
using red phosphorus clusters before each measurement. After MALDI measurements, all tissue 
sections were stained with hematoxylin and eosin (H&E), digitally scanned with the Mirax digital 
slide scanning system (Zeiss, Jana, Germany) and evaluated through histology by an experienced 
uropathologist. 
To verify that ZnCl3- can be created from zinc and chloride ions by the MALDI-TOF process, ZnCl2 
standards (Sigma-Aldrich) were also measured by the rapifleX instrument. ZnCl2 was dissolved in 
100% ethanol to produce concentrations of 1, 2.5, 5 and 10 mg/mL, and 1µL of each solution was 
placed on ITO glass slides and left to dry. MALDI-TOF measurements were performed both on ZnCl2 
standards covered with NEDC matrix (same parameters as previously described) and uncovered ZnCl2 
standards.  
High mass resolution acquisition and tandem MS for identification of citrate, aspartate and NAA were 
performed on the MALDI-Orbitrap system Q ExactiveTM HF Hybrid QuadrupoleTM (Thermo Fisher 
Scientific GmbH, Bremen, Germany) coupled to a MALDI/ESI injector (Spectroglyph LLC, 
Kennewick, WA, USA). Tandem-MS was performed using higher-energy collisional dissociation cell 
with an isolation window of ±0.5 Da, a normalized collision energy in the range of 20-65 
(manufacturer units), laser shot frequency of 1000 Hz, and a mass resolution of 240,000 (FWHM at 
m/z 200). For each precursor, 20 spectra were acquired using an injection time of 2000 ms per scan 
while continuously moving the stage. Additionally, imaging measurements were performed using 
MALDI-Orbitrap (m/z 160-180, spatial resolution 30 µm, 1000 Hz laser frequency and 550 ms 
injection time) in negative ion mode in order to identify masses that may be overlapping with the 
isotopic ZnCl3- masses in the MALDI-TOF experiments. Measurements of two core sample sections 
had to be disregarded due to a problem with the ion transmission of the source, leaving us with 
imaging data of one core sample and one biopsy sample. All MALDI-Orbitrap measurements were 
performed on samples covered with NEDC matrix according to the previously described spraying 
method. 
LA-ICP MSI experiments 
To validate that the spatial detection of ZnCl3- with MALDI is representative of total zinc distribution 
in the tissue, LA-ICP-MSI for total zinc detection was performed on adjacent tissue sections from that 
of MALDI-TOF MSI measurements. The tissue samples were analyzed at a spatial resolution of 15 
µm with an ICPMS-2030 instrument (Shimadzu, Kyoto, Japan) coupled to the laser ablation system, 
LSX-213 G2+ (Teledyne Cetac, Omaha, USA). Samples were ablated via line-by-line scan with a 
pixel size of 15 µm, a scan speed of 45 µm/s and 800 mL/min He as transport gas. The analysis was 
performed in collision gas mode with He as collision gas. Integration time for 64Zn and 66Zn were 75 
ms. For the quantification of Zn, matrix-matched standards based on gelatin were used. Eight gelatin 
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standards (10% w/w) including a blank, were spiked with different Zn concentrations ranging from 1 
to 500 µg/g. A separate test tissue section placed on the same glass slide was used to optimize the 
ablation process for each measurement. 
Data preprocessing  
FlexImaging v4.1 (Bruker Daltonics) was used to co-register the H&E stained and scanned histology 
images to the MALDI-TOF MSI measurements. In this software, the histopathology annotations for 
the core samples were used to define regions of interest (ROI): non-cancer epithelium, stroma, and 
cancer. In cases of less successful histology co-registrations (evident by shifts in histology images 
compared to on-tissue measurements), an in-house R-script was used to adjust the X and Y 
coordinates of the ROIs in the –mis-file (flexImaging specific file) to fit the MSI measurement 
(Supplementary Script S1). All core samples measurements were combined using SCiLS Lab 2016b 
(SCiLS GmbH, Bremen Germany) with a convolution baseline subtraction (width: 75). Each 
spectrum was normalized by its total ion count. For the core samples, the acquired single spectra were 
organized into either non-cancer epithelium, stroma or cancer, according to the histology annotations 
and exported as CSV-files. An in-house R-script (Supplementary Script S2) was used to extract the 
peak intensity of aspartate (m/z 132.02), NAA (m/z 174.04), citrate (m/z 191.02) and the isotopic 
peaks of ZnCl3- (m/z 168.84, 170.83, 171.83, 172.83, 173.82 174.82, 175.82, 176.82, 177.82 and 
178.82). Peak intensity was defined as the highest point of a peak. Thermo Xcalibur 3.0.28 (Thermo 
Fisher Scientific, Bremen, Germany) was used to analyze the MALDI-Orbitrap imaging 
measurements. For visualization, the imaging data was converted to mzXML format using 
RawConverter18 and analyzed using an in-house built MATLAB GUI.19-20 
The metabolites aspartate, NAA and citrate were identified through comparing the tandem MS spectra 
to the theoretical or validated measured fragment spectra in databases, including METLIN 
(https://metlin.scripps.edu)21 and the Human Metabolome Database (http://www.hmdb.ca/).22 
Statistical analysis 
Pearson statistics in R were used to calculate the match between the measured and theoretical ZnCl3- 
isotopic peak patterns and to investigate the spatial relation between zinc and the metabolites aspartate 
and citrate. The theoretical isotopic pattern of ZnCl3- were obtained from ChemCalc.org23 with the 
mass resolution comparable to both the MALDI-TOF and MALDI-Orbitrap measurement, 3000 and 
240 000 FWHM, respectively. The corr.test function from the psych package24 was used to calculate 
the correlation between the analytes, and the correlation plots were created with the package 




To investigate the biological association between zinc, citrate, aspartate and NAA, and the different 
tissue components (non-cancer epithelium, stroma and cancer), univariate linear mixed models 
(LMM) were performed in R with the nlme v3.1-137 package26 (Supplementary Script S3). LMM was 
used in order to include patient origin as a random effect. Due to overlapping masses for some of the 
isotopic peaks of ZnCl3-, the m/z 174.82 mass was used to represent zinc, as this would exclude any 
interference from other masses. LMM was performed by randomly selecting 0.5% of the spectra to 
build models. This strategy was used to limit the effect of spatial autocorrelation, common to MSI 
data.27 Choosing a fraction of 0.5% limits the average number of neighboring pixels selected to 
approximately 3.9%, according to probability statistics (P(A1 ∪ A2 …  ∪ A8) = 1- 0.9958, where A1-8 
are neighboring pixels). This fraction based LMM was repeated 1000 times for each mass for each 
pairwise comparison, and the mean p-value and log2 fold change (log2FC) was calculated. A p-value 
below 0.05 was considered significant. For LMM models to be valid, the residuals need to be 
normally distributed. An automatized strategy was used to assess normality for each model (described 
in Supplementary Text S1). In cases where the models failed the normality assumption, the peak 
intensity levels were log transformed and a new LMM model were calculated. A second normality fail 
would cause exclusion of that iteration.  
 
Results and Discussion 
Zinc can be detected with MALDI MSI in prostate tissue 
ZnCl3- was initially discovered in our prostate core samples MALDI-TOF MSI dataset (n=45), by 
manual untargeted spectral and spatial mass distribution evaluation. We found that the m/z 168.84 
mass had a similar spatial distribution (Supplementary Figure S1) to eight other ions with higher m/z 
values approximately 1 or 2 Da apart (m/z 170.83, 171.83, 172.83, 173.82 174.82, 175.82, 176.82, 
177.82 and 178.82). This strongly suggested that the nine masses were isotopic peaks representing the 
same compound. Based on the mass defect and isotope pattern the ions were assumed to belong to an 
inorganic molecule. Searching in METLIN21 for the monoisotopic mass (m/z 168.84), gave ZnCl3- as a 
possible identity. Further investigating the isotopic peak pattern of ZnCl3- confirmed that the nine 
masses represented the different combinations of stable isotopes of zinc (64Zn, 66Zn, 67Zn and 68Zn) 
and chloride (35Cl and 37Cl). However, according to the theoretical isotopic spectrum (Figure 3a, top 
spectrum), the second mass (m/z 170.83) should be the most abundant mass, while the mean spectrum 
from our dataset (Figure 3a and Supplementary Data) indicated the monoisotopic m/z 168.84 mass to 
be the most abundant. A lower mass of m/z 166.85 was suspected to interfere by having isotopic 
masses overlapping with some of the ZnCl3- isotopic peaks. Further investigation revealed the m/z 
166.85 mass to be tetrachloroaluminate (AlCl4-) as presented in Supplementary Text S2 and 
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Supplementary Figures S5-S7. By creating a new mean spectrum with five different ROIs that had 
high ZnCl3- levels (Figure 3a and Supplementary Data), thereby minimizing the interference from m/z 
166.85, a spectrum more similar to the theoretical spectrum was produced. This high zinc level 
spectrum had a significantly high correlation with the theoretical spectrum of ZnCl3- (r=0.996, 
p=1.92*10-8). This initial discovery was based on analysis of NEDC matrix covered tissue samples. A 
second smaller sample set, consisting of CMC and gelatin embedded biopsy samples (n=4) covered 
with 9-AA matrix, did also show detection of the ZnCl3- isotopic peaks (Supplementary Figure S2). 
This demonstrates that ZnCl3- can be detected in prostate tissue with different matrices and using 




Figure 3: Measured isotopic peak pattern compared to theoretical pattern of zinc trichloride 
(ZnCl3-). (a) The theoretical isotopic peak pattern of ZnCl3- (top spectrum, FWHM=3000, from 
ChemCalc.org23) were compared to the mean spectrum measured by MALDI-TOF MSI acquisition 
(middle spectrum). Due to a contaminating molecule (m/z 166.85) likely to have interfering isotopic 
masses, a mean spectrum was created from selected regions of interests (ROIs) with high ZnCl3- 
contents. This high- ZnCl3- spectrum proved to be very similar to the theoretical spectrum. (b) A 
separate measurement using high mass resolution MALDI-Orbitrap (Bottom spectrum) were also 
compared to the theoretical isotopic peak pattern (FWHM=240 000, ChemCalc.org) and additionally 
showed (c-e) a matching isotopic fine structure. Transparent red indicates detected ZnCl3- isotopic 
peaks. Abbreviation: r. int. = relative intensity 
11 
 
To our knowledge, this is the first reported ZnCl3- detection in any tissue sample. ZnCl3- has 
previously been reported as a side-product in chemical reactions using MS methods.28-30 Hou et al. 
demonstrated detection of ZnCl3- using MALDI-TOF with NEDC matrix in solutions of ZnCl2 and in 
samples of lake water, but could not detect ZnCl3- in biological samples such as urine and plasma.15 
At this point, a likely explanation is that ZnCl3- forms in the MALDI process through tissue specific 
zinc (from salts or biological complexes) that pair up with excess chloride ions. We first hypothesized 
that the excess chloride ions may originate from the NEDC matrix which is applied as a solution of its 
hydrochloride salt. Using MALDI-TOF on ZnCl2 standards, both with and without NEDC matrix, 
confirms that ZnCl3- can be created from ZnCl2 alone in the MALDI process (Supplementary Figure 
S3). We further performed MALDI-TOF measurements using chloride-free 9-AA matrix on prostate 
tissue, and were still able to detect ZnCl3-, but at a lower sensitivity (Supplementary Figure S4). 
However, this matrix gave lower sensitivity for other masses as well (e.g. citrate was not detected), 
indicating a generally lower ionization efficiency of this matrix. Based on our own and others results 
that has successfully used NEDC for metal detection,15 we would perform subsequent experiments 
using this matrix for ZnCl3- detection. 
In order to acquire accurate mass of ZnCl3- and identify the contaminating peak of m/z 166.86 
(Supplementary Text S2), an additional high mass resolution acquisition was performed using 
MALDI-Orbitrap. A total of 14 isotopic ZnCl3- peaks were detected with a mass error of less than 2 
ppm (Figure 3b and Supplementary Data). We were further able to separate the isotopic fine structure 
for the m/z 172.83, 174.83 and 176.83 masses (Figure 3 c-e), which explains the higher number of 
detected isotopic peaks compared to MALDI-TOF. Similar to MALDI-TOF, the mean MALDI-
Orbitrap spectrum of the detected ZnCl3- masses had similar high degree of correlation with the 
theoretical isotopic masses (r=0.999, p=2.2*10-16). 
Spatial ZnCl3- distribution matches total zinc detection 
LA-ICP MSI is a well-established method to quantitatively image total metal content, including total 
zinc, in prostate tissue.13 Thus, to further verify the results from MALDI-TOF MSI, we performed 
LA-ICP MSI on an adjacent serial tissue section for absolute quantification and distribution analysis 
of zinc (64Zn). The aim was also to see if the distribution of ZnCl3- is representative of total zinc 
distribution. From visual assessment, there is a general agreement between the spatial distribution of 
ZnCl3- and total zinc detected with MALDI-TOF MSI and LA-ICP MSI, respectively (Figure 4 and 
Supplementary Figure S8). We note that non-optimal tissue integrity for some of the validation 
samples made the match between sections measured with LA-ICP-MSI and MALDI-TOF MSI less 
apparent (see Supplementary Figure S8), although roughly the same areas of the sections show a 
similar zinc distribution. Additionally, when comparing to the stained histology sections, elevated 
12 
 
levels of zinc are localized to non-cancer epithelial glands for both measurements. Overall, this adds 
further evidence that MALDI MSI can reliably be used for zinc detection. 
 
Figure 4: Heat-maps comparing MALDI MSI to LA-ICP MSI for spatial zinc detection. (a) 
Total zinc detected with LA-ICP MSI had a matching spatial distribution with ZnCl3- detected with 
both (b) MALDI-Orbitrap and (c) MALDI-TOF MSI. (d) Annotated histopathology of the sections 
used for MALDI-TOF MSI further showed that high zinc levels are located to non-cancer epithelium. 
A part of the section used for (b) MALDI-Orbitrap was lost during cryosectioning. 
 
Zinc is correlated to citrate and aspartate 
In addition to being substantially faster, a major strength of using MALDI-TOF MSI for imaging zinc 
compared to LA-ICP MSI, is that the former method is also capable of simultaneously detecting small 
metabolites that are closely biologically related to zinc. Two such metabolites are citrate and aspartate 
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(Figure 1), which we detected in the exact same MALDI-TOF MSI measurements. Zinc (ZnCl3-, m/z 
174.82) was significantly correlated with citrate (r=0.64) and aspartate (r=0.46), while citrate and 
aspartate had a stronger correlation with each other (r=0.74, Figure 5a) (p<0.001). The lower 
correlation between zinc and aspartate suggest that zinc is closely linked to citrate and further away 
from aspartate in the metabolic pathway (Figure 1). Overall, our results further support the previous 
findings that high levels of zinc leads to high levels of citrate,1 and that aspartate is one of the key 
carbon sources for citrate production2.  It should be noted that these findings are metabolic snapshots 
and does not prove the direct mechanistic association between zinc, citrate and aspartate. However, 
the correlation analysis is based on more than 190 000 spectra, originating across 45 tissue samples 
with a range of different histology features, adding substantial confidence to the results. The spatial 
distribution of the masses used for correlation analysis on the core samples is presented in 
Supplementary Figure S9. 
Performing separate correlation analysis on spectra from only non-cancer epithelium and from stroma, 
still showed similar correlations between zinc, aspartate and citrate (Figure 5b-c). However, in cancer 
these correlations were lower (Figure 5d). This may indicate that the zinc-citrate-aspartate pathway 
mechanism present in healthy prostate epithelium gets more obstructed during prostate cancer 
development. 
Currently, aspartate for citrate production is thought to be largely imported, based on the reported 
high level of the aspartate transporter in benign prostate epithelium.31 Aspartate can also be 
synthesized inside the cell from NAA3 (Figure 1), a reversible reaction. However, this mechanism has 
not been reported to be an important source of aspartate in healthy prostate epithelium. Interestingly, 
the correlation between NAA and aspartate in non-cancer epithelium is relatively low (r=0.17), while 
a higher correlation is found in stroma and cancer (Figure 5b-d). The low correlation in non-cancer 
epithelium supports the current knowledge that aspartate in healthy prostate tissue may be 
predominantly imported to facilitate citrate production.31 During cancer progression, import is halted 
and aspartate may be more associated with conversion to/from NAA, causing an increased correlation. 





Figure 5: Correlation analysis of zinc and relevant metabolites. Pearson statistics were used to 
calculate correlation between zinc, citrate (Cit), aspartate (Asp) and N-acetylaspartate (NAA) for (a) 
all spectra, (b) non-cancer epithelium spectra, (c) stroma spectra and (d) cancer spectra. The figure 
was made using the corrplot package25 in R. 
 
Significantly reduced levels of zinc, citrate and aspartate in prostate cancer tissue 
Pairwise univariate LMM and log2FC showed that zinc, citrate and aspartate were significantly 
reduced in cancer compared to non-cancer epithelium tissue (Table 1). Lower levels of zinc and 
citrate in prostate cancer is largely reported before,6-8, 32 and have been linked to a worse clinical 
outcome.5, 9 However, this is the first time the spatial distribution of zinc has been shown on 
heterogeneous tissue sections using MALDI MSI (Figure 6). Zinc had a larger decrease than citrate 
and aspartate in cancer compared to non-cancer epithelium (log2FC=-0.99, p=0.0019), and were more 
spatially localized to non-cancer epithelial glands (Figure 6). This makes zinc a potential marker to 
aid the identification of glands that may be cancerous. It should be noted that the non-cancer 
epithelium regions used for analysis in this study came from malignant prostates and may not be 
considered truly healthy tissue. Due to ethical concerns, it is highly unusual to get access to normal 
and metabolically preserved prostate tissue from healthy men. Although this can limit elucidation of 
the full biological development of prostate cancer, it is more clinically relevant to differentiate 
cancerous glands from i.e. benign prostate hyperplasia which is a highly common non-cancerous 
condition in older men. 
Our results also show that stroma has comparable decreased levels of zinc, citrate and aspartate to 
cancer tissue, demonstrating how stroma content in prostate tissue samples can confound whole-
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sample metabolic analysis of prostate samples, such as nuclear magnetic resonance spectroscopy 
(NMRS) and liquid chromatography-MS (LC-MS). This pinpoints the value of methodology that 
maintains spatial information, especially in biomarker research based on analyzing heterogeneous 
cancer samples. 
In contrast to zinc, citrate and aspartate, NAA had higher levels in cancer compared to stroma 
(log2FC=1.169, p=0.024) and a tendency of higher levels when comparing to non-cancer epithelium 
although not significant (log2FC=0.849, p = 0.14). Elevated levels of NAA have previously been 
identified  in ovarian33, lung,34 and prostate cancer.35 The specific role of NAA in cancer development 
remains unclear, but may be related to increased lipid synthesis,36 a well-established phenomenon of 
different cancer types, including prostate cancer.37 
 
Table 1: Linear mixed models (LMM) and log2 fold change (log2FC) were used to investigate 
differences in levels of zinc (ZnCl3-) and relevant metabolites, citrate, aspartate and N-acetylaspartate 
(NAA), across the tissue types: non-cancer epithelium (NCE), stroma and cancer. 












132.03 Aspartate 0.617 4.90E-07* -0.423 0.00018* 0.197 0.5 
174.04 NAA 0.311 0.32 0.849 0.14 1.169 0.024* 
191.02 Citrate 0.83 1.40E-11* -0.695 0.00016* 0.138 0.41 
174.82 ZnCl3- 0.789 7.70E-06* -0.987 0.0019* -0.197 0.39 
*Significant p-value from univariate LMM 
 
 
Figure 6: Comparison of the spatial distributions detected with MALDI-TOF MSI. (a) Aspartate 
and (b) citrate had a very similar spatial distribution with (c) zinc (ZnCl3-). (d) The spatial 
distributions of these three masses also matched to annotated non-cancer epithelium. 
 
Implications of ZnCl3- detection with MALDI MSI 
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MALDI MSI is not generally recommended for detection of metals and metal containing molecules 
on tissue due to a low ionization efficiency.38 It was therefore unexpected to identify ZnCl3- in our 
dataset. As reduced levels of zinc have been reported for a number of different cancers, including 
lung, breast and liver,39 investigating the potential detection of ZnCl3- in other human tissues would be 
of interest. However, a very relevant underlying fact of our novel finding, is that the prostate gland 
has an unusual high concentration of zinc, as much as 10-20 fold compared to other tissues.1 
Consequently, zinc detection with MALDI MSI on other tissues may be more challenging than 
prostate tissue due to substantial lower concentrations. 
Due to the simultaneous detection of zinc (ZnCl3-) together with other relevant metabolites, we could 
successfully investigate these close metabolic relationships. Further research of the diagnostic and 
prognostic value of these molecular features detected with MALDI, both singularly and in 
combination, on a larger patient cohort, may reveal robust clinical biomarkers. Both zinc and citrate 
are previously proposed biomarkers, due to their systematic reduction in prostate cancer.5-7, 32, 40 
Importantly, simultaneous detection of these compounds in the same measurement without any 
additional experimental adjustments, make them more interesting as clinical biomarkers. MALDI-
TOF MSI instrumentation, such as rapifleX, are additionally proposed as clinical tools due to their 
high speed, making rapid diagnostics possible.41-42 
 
Conclusion 
In this study, we have demonstrated the spatial detection of the cancer biomarker zinc, in the form of 
ZnCl3-, on prostate tissue using MALDI-TOF MSI. This method can detect a wide range of molecules, 
which enabled us to simultaneously detect the metabolically closely associated metabolites citrate, 
aspartate and NAA. We identified clear biological associations between zinc, citrate and aspartate, 
and tissue type, where all features were correlated with each other and were reduced in cancer 
compared to non-cancer epithelium. Simultaneous spatial detection of zinc and citrate, in particular, 
with MALDI-TOF MSI may be a promising tool both for prostate cancer diagnosis and prognosis. 
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